Twitxy Saved

Brandon Huffman, MD

@BHuffmanMD

GI medical oncologist @DanaFarber | @MayoMN_IMRES | @MUMedicine | Tweets my own. Interests: GI cancers, Clinical Trials, Targeting KRAS, #pancsm
525 Following 1.2K Followers 1.7K Posts

Latest posts 5

Brandon Huffman, MD @BHuffmanMD
Updated efficacy and safety of initial cohorts for zecdarasib (INCB161734) with chemo (Abstract 3137RO) will be presented by Dr. @HollebecqueA at #ESMO26.

GnP combo ORR: 62.5%
FFX combo ORR: 75%

Looking forward to seeing the presentation! 👀

@KRASKickers #kras
OncLive.com Verified account @OncLive Oct 20
🗣️ "[INCB161734] binds the switch II pocket of mutant KRAS with a G12D mutation with picomolar affinity, and it shows a greater than 80-fold selectivity over wild-type KRAS," said @BHuffmanMD of @DanaFarber on INCB161734 and how the phase 3 DAWN-303 trial is testing it in metastatic pancreatic cancer.

Full video 📰: onclive.com/view/dr-huffma…

#pancsm #oncology
View quoted post on X
Brandon Huffman, MD @BHuffmanMD
Thank you for inviting me to talk about the evolving landscape in pancreatic cancer at the #MSCO Fall Conference! It was my pleasure to share our experience as these new treatments emerge for #PDAC. The future is targeting #KRAS.
Jasmine Kamboj, MD, FASCO Verified account @JasmineKambojMD Sep 23
Eloquent talk by @BHuffmanMD of @DanaFarber @DanaFarberNews at the #MSCO Fall conference in Minneapolis.

👏🥳👏🥳

@ASCO @ASCOPost @MayoCancerCare @MayoClinic @MayoMedEd @KLeventakos
View quoted post on X